Trial Profile
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Futuximab/modotuximab (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Therapeutic Use
- 08 Jul 2020 Status changed from active, no longer recruiting to completed.
- 15 Aug 2019 Planned End Date changed from 1 Jan 2021 to 1 Aug 2021.
- 11 Jun 2019 Planned End Date changed from 1 May 2020 to 1 Jan 2021.